AASS
Alpha-aminoadipic semialdehyde synthase, mitochondrial
Also known as: AASS_HUMAN, LKRSDH, LORSDH
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UDR5
- Gene
- AASS
- Ensembl
- ENSG00000008311
- Chromosome
- 7
- Canonical length
- 926 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Vesicles,Mitochondria
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a bifunctional enzyme that catalyzes the first two steps in the mammalian lysine degradation pathway. The N-terminal and the C-terminal portions of this enzyme contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively, resulting in the conversion of lysine to alpha-aminoadipic semialdehyde. Mutations in this gene are associated with familial hyperlysinemia. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
926 residues, UniProt reviewed canonical sequence.
>Q9UDR5|AASS
1 MLQVHRTGLG RLGVSLSKGL HHKAVLAVRR EDVNAWERRA PLAPKHIKGI TNLGYKVLIQ
61 PSNRRAIHDK DYVKAGGILQ EDISEACLIL GVKRPPEEKL MSRKTYAFFS HTIKAQEANM
121 GLLDEILKQE IRLIDYEKMV DHRGVRVVAF GQWAGVAGMI NILHGMGLRL LALGHHTPFM
181 HIGMAHNYRN SSQAVQAVRD AGYEISLGLM PKSIGPLTFV FTGTGNVSKG AQAIFNELPC
241 EYVEPHELKE VSQTGDLRKV YGTVLSRHHH LVRKTDAVYD PAEYDKHPER YISRFNTDIA
301 PYTTCLINGI YWEQNTPRLL TRQDAQSLLA PGKFSPAGVE GCPALPHKLV AICDISADTG
361 GSIEFMTECT TIEHPFCMYD ADQHIIHDSV EGSGILMCSI DNLPAQLPIE ATECFGDMLY
421 PYVEEMILSD ATQPLESQNF SPVVRDAVIT SNGTLPDKYK YIQTLRESRE RAQSLSMGTR
481 RKVLVLGSGY ISEPVLEYLS RDGNIEITVG SDMKNQIEQL GKKYNINPVS MDICKQEEKL
541 GFLVAKQDLV ISLLPYVLHP LVAKACITNK VNMVTASYIT PALKELEKSV EDAGITIIGE
601 LGLDPGLDHM LAMETIDKAK EVGATIESYI SYCGGLPAPE HSNNPLRYKF SWSPVGVLMN
661 VMQSATYLLD GKVVNVAGGI SFLDAVTSMD FFPGLNLEGY PNRDSTKYAE IYGISSAHTL
721 LRGTLRYKGY MKALNGFVKL GLINREALPA FRPEANPLTW KQLLCDLVGI SPSSEHDVLK
781 EAVLKKLGGD NTQLEAAEWL GLLGDEQVPQ AESILDALSK HLVMKLSYGP EEKDMIVMRD
841 SFGIRHPSGH LEHKTIDLVA YGDINGFSAM AKTVGLPTAM AAKMLLDGEI GAKGLMGPFS
901 KEIYGPILER IKAEGIIYTT QSTIKPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AASS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 47 nTPM
Expression across tissuesHPA
Tissue
- liver: 47 nTPM
- ovary: 45 nTPM
- choroid plexus: 23 nTPM
- blood vessel: 19 nTPM
- fallopian tube: 19 nTPM
- pancreas: 18 nTPM
Single-cell type
- hepatocytes: 392 nCPM
- schwann cells: 296 nCPM
- ovarian stromal cells: 273 nCPM
- bergmann glia: 251 nCPM
- thymic myoid cells: 223 nCPM
- astrocytes: 211 nCPM
Immune cell
- memory B-cell: 0.1 nTPM
- T-reg: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- choroid plexus: 19 nTPM
- basal ganglia: 12 nTPM
- white matter: 11 nTPM
- medulla oblongata: 11 nTPM
- midbrain: 9.9 nTPM
- thalamus: 9.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AASS.
Disease | AllUniProt
Conditions AASS is implicated in, by any mechanism.
- Hyperlysinemia, 1 (HYPLYS1) MIM:238700
- 2,4-dienoyl-CoA reductase deficiency (DECRD) MIM:616034
Disease | GeneticClinVar
23 pathogenic / likely-pathogenic of 315 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hyperlysinemia
- HYPERLYSINEMIA, TYPE I
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.81
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.88
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- L-lysine catabolic process to acetyl-CoA via saccharopine
- lysine biosynthetic process via aminoadipic acid
- lysine catabolic process
- negative regulation of transcription by RNA polymerase II
Molecular functions
- histone binding
- transcription corepressor activity
- saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity
- saccharopine dehydrogenase (NAD+, L-lysine-forming) activity
- saccharopine dehydrogenase (NADP+, L-lysine-forming) activity
- saccharopine dehydrogenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Saccharopine dehydrogenase, NADP binding domain
- Alanine dehydrogenase/pyridine nucleotide transhydrogenase, NAD(H)-binding domain
- Alanine dehydrogenase/pyridine nucleotide transhydrogenase, N-terminal
- NAD(P)-binding domain superfamily
- Saccharopine dehydrogenase NADP binding domain
- Alanine dehydrogenase/PNT, N-terminal domain
- Saccharopine dehydrogenase-like, C-terminal
- Alpha-aminoadipic semialdehyde synthase
- Saccharopine dehydrogenase C-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AASS as an antibody target. Whether an autoantibody or antibody against AASS could matter depends on whether native AASS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AASS is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AASS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...